This is freakin' ridiculous!!!
Out of town travelling until tomorrow night, computer on the fritz and just iPhone working!!! Stupid dog (short) tricks today. shorts seem to have pulled out all the stops (literally) as they did on the bear raid a week ago. That's why I always keep dry powder and take advantage. My buy average after doubling down last week at $.86 is under a buck. Tomorrow I will buy more. Approval is a lay up, the study was under a SPA (special protocol assessment) and was highly statistically significant. Macrilen is WAY, WAY SAFER than Insulin injections and FDA always approves safer drugs (safety over efficacy). Finally my homies at HC Wainright are obviously up on the process and the "labelling discussions" that are going on. Even WITHOUT MACRILEN we are undervalued as we are pretty much trading near cash. Our Phase III asset, pipeline and commercial sales force and partnerships are being valued at zero - that means there is no real downside here (maybe another dime) and about 500% upside. Investing is all about risk / reward and the reward far outweighs any risk. No brainer as far as I'm concerned. Good Luck Longs - see you tomorrow night or Friday!!!
OXGN starting another Phase II trial in GI NETS - it's a rollover study, we must already be seeing positive results in the first study!!! Yehawwww!
We're on the BIG PHARMA radar it's gonna happen just a matter of time when you're trading below cash. We have $225 Million on NOL tax credits. Someone can take us out for $2.00 / share and still put money in their pocket.
Looks like we will soon have a 2nd marketed product with a 3rd by Year End!!! Congratulations Longs!
Let's face it, after Centroelix and Perifosine there are many, many who have lost a ton 'o' money on AEZS. So now the are immature and bitter. Emotional types who don't know how to take a loss like a man. So now they short and bash, trash the CEO in long winded 1,500 essays etc. The are spiteful and vengeful and want to hurt the company and current investors by driving it outta business. Too bad, it ain't gonna happen, this company has had an unfortunate past, many, many Biotechs have. It's the risks involved with drug development etc. But Dodd has a plan and so far that plan is working, in the long run if shorts bet against it they will lose - AGAIN! I guess once a loser always a loser, oh well, its their lot in life
Another year has passed, no price appreciation, in fact we were over $3.00++ last Fall. Where's the ATC filing in EU? What year was the Phase I Oxi4503 trial to be competed 2017, 2018, 2019?? What are you guys doing to unlock the value in the pipeline and assets? PUT THIS COMPANY UP FOR SALE NOW!!!